Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.34B P/E 59.23 EPS this Y 7.80% Ern Qtrly Grth 14.10%
Income 681.8M Forward P/E 12.74 EPS next Y 6.20% 50D Avg Chg -
Sales 6.26B PEG 1.63 EPS past 5Y 17.70% 200D Avg Chg 10.00%
Dividend N/A Price/Book 3.25 EPS next 5Y 8.49% 52W High Chg -3.00%
Recommedations 2.70 Quick Ratio 3.47 Shares Outstanding 221.02M 52W Low Chg 83.00%
Insider Own 0.27% ROA 10.08% Shares Float 220.65M Beta 1.26
Inst Own 88.02% ROE 4.43% Shares Shorted/Prior -/- Price 182.50
Gross Margin 90.94% Profit Margin 10.89% Avg. Volume 4,222,993 Target Price 177.36
Oper. Margin 47.41% Earnings Date Oct 27 Volume 3 Change 0.00%
About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.

ALXN Chatroom

User Image Newsfilter Posted - 2 days ago

$ALXN Potential Drug Interaction Between ALXN2040 and Rosuvastatin - NCT05708573 https://newsfilter.io/a/fb1e30caad7f379f0f230a845f9efcda

User Image macroaxis Posted - 01/29/23

$ALXN - Sale by Carsten Thiel of 1000 shares of… https://www.macroaxis.com/invest/story/ALXN/25436742/Sale-by-Carsten-Thiel-of-1000-shares-of-Alexion-Pharmaceuticals #insidertrading #stocks #fintechnews

User Image ern1in Posted - 01/24/23

$ALXN & $TGTX 1/24/2023 Evercore adjusts price target on TG Therapeutics to $25 from $16, maintain Outperform Rating. Strong Buys & Strong Holds.

User Image macroaxis Posted - 01/22/23

$ALXN - Sale by Heidi Wagner of tradable shares of… https://www.macroaxis.com/invest/story/ALXN/25335188/Sale-by-Heidi-Wagner-of-tradable-shares-of-Alexion-Pharmaceuticals #insidertrading #stocks #fintechnews

User Image Newsfilter Posted - 01/17/23

$ALXN Early Access Program for ALXN1840 in Patients With Wilson Disease - NCT05686564 https://newsfilter.io/a/28237afaf191ca583c02ffd548aa2982

User Image ern1in Posted - 12/29/22


User Image Newsfilter Posted - 12/09/22

$ALXN Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis - NC.. https://newsfilter.io/a/5bdc53e65142996755be618533b57801

User Image Newsfilter Posted - 12/07/22

$ALXN Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants - NCT05641311 https://newsfilter.io/a/f504e9ab7adda2056c82f5f1210d0c17

User Image MF__DOOM Posted - 11/28/22

$AXSM $QURE both did well and approved no surprise… waiting for πŸ§¬πŸ“° EVFM Q10 to drop today or AH should see similar movement Other bios trending: $ALXN $LABU $XBI

User Image macroaxis Posted - 11/26/22

$ALXN - Pin risk slides as more Alexion Pharmaceuticals call traders are getting in https://www.macroaxis.com/stock-options/ALXN/Alexion-Pharmaceuticals?utm_source=dlvr.it&utm_medium=stocktwits

User Image cctranscripts Posted - 11/16/22

Tender offer statement by Third Party https://www.conferencecalltranscripts.org/summary/?id=11517725 $ALXN

User Image Sparky202 Posted - 10/20/22

$AUPH $XERS is running just like AUPH. Let's recap why XERS is up today: Positive results THIS MORNING on SubQ Levothyroxine using Xeriject technology, potential $1-2B market. 3 other approved products, all growing revenue. Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings. Expanding sales force to penetrate new markets for much needed drugs. Ogluo royalties starting in EU. Collaborations with 4 big pharma, one is MRK. Other 3 big pharma collabs at "Decision Stage." They keep maintaining guidance and CF+ 2023. Unlike most clinical biotechs, they are actually selling tens of millions of product, soon to be hundreds of millions. CEO has built and sold 2 prior biotechs successfully. What is not to love? Cheers! $TEVA $ALXN

User Image Newsfilter Posted - 10/13/22

$ALXN Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics - NCT05578846 https://newsfilter.io/a/93d9cbf8595d83a87956f66a45373ea7

User Image cctranscripts Posted - 4 months ago

Written communication relating to an issuer or third party https://www.conferencecalltranscripts.com/summary/?id=11358330 $ALXN

User Image Newsfilter Posted - 09/27/22

$ALXN Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis - NCT05556096 https://newsfilter.io/a/0d286758e32a723b8265a3d840429155

User Image macroaxis Posted - 09/13/22

$ALXN - Option Volatility signal: Alexion Pharmaceuticals pin risk is sliding https://www.macroaxis.com/stock-options/ALXN/Alexion-Pharmaceuticals?utm_source=dlvr.it&utm_medium=stocktwits

User Image bigwhalealert Posted - 09/07/22

$ALXN BUY/SELL METER Alert Cross 13% +- Technical Analysis https://t8sk.com/ALXN

User Image Newsfilter Posted - 08/15/22

$ALXN Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants - NCT05501717 https://newsfilter.io/a/d4d1af94ed4bfdc8038e91991ea557ae

User Image bigwhalealert Posted - 08/12/22

$ALXN BUY/SELL METER Alert Cross 13% + πŸš€ https://t8sk.com/ALXN

User Image bigwhalealert Posted - 08/10/22

$ALXN - BUY/SELL METER NOW🦍: https://t8sk.com/ALXN- 16% πŸš€

User Image GeorgeTheo Posted - 6 months ago

$SLS Analyst are calling for $200 million in Gps sales for the first AML indication, secondary remission plus $800 million more through an expanded label are plenty good reason for SLS shares to Jump. Do the math Biotech jump like that all the time - look at $CPXX. I remember $ALXN jumped from $4 to $120 twice in a week - settled back in the $30's before running up to a few splits. $SGEN a $4 stock forever, shot up on approval. bounced off $200. This will be Happening Here.

User Image macroaxis Posted - 07/13/22

$ALXN - Alexion options price alert: put open interest is down to 327.0 https://www.macroaxis.com/stock-options/ALXN/Alexion-Pharmaceuticals?utm_source=dlvr.it&utm_medium=stocktwits

User Image streamwars Posted - 06/24/22

$AZN is up, $MREO is way down. Says to me that this "buy out" was just a rumour, designed to pump MREO up above the Nasdaq dollar. Astrazeneca already has a similar / better drug in the pipeline and already has a licensing deal with MREO. They do not need to buy the company. Why would they as they are still paying for the excellent deal they made with $ALXN? I tried to warn you folk at MREO.

User Image Newsfilter Posted - 06/23/22

$ALXN Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants - NCT05428696 https://newsfilter.io/a/23ec9c3ad4d9aead5c2c1fa6340cea45

User Image patatechaude Posted - 06/23/22

$AKTX Soliris ($ALXN now $AZN) for PNH sales @ +$1B and Rachelle brings Nomacopan for PNH back on the table (on top of a rich list of potential rare disease indications). $AKTX could be one of the biggest $XBI gainer of the next few years. $1 is a gift.

User Image patatechaude Posted - 06/22/22

$AKTX New COO starts in July. Rachelle is pumped up by the potential she sees at Akari. The next few months should bring good news. Time to make Akari the Billion$ biotech it’s meant to be. $ALXN waiting to happen.

User Image Trinitrade Posted - 06/21/22

$MREO Even shorts are fake. Scaring retail into selling. $AZN bought out $ALXN just last year ppl and it all started with supossed rumor. How soon we forget. πŸŽ„πŸ’ΈπŸŽ„πŸ’ΈπŸŽ„πŸ’ΈπŸŽ„πŸŒ‹πŸŒ‹πŸš€πŸš€πŸš€

User Image Newsfilter Posted - 06/15/22

$ALXN Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease - NCT05419765 https://newsfilter.io/a/c028bb9d9e767a0ba44ee703d851b3c6

User Image AuphAurinia Posted - 06/04/22

$AUPH Positive news from $BMY acquisition leading market higher $XBI. Until doubt remain on longevity patent, we will stay where we are. Comparable situation happened to $ALXN a year before its acquisition by $AZN

User Image patatechaude Posted - 05/12/22

Time to buy $AKTX if you’re not in yet. $ALXN competitor in the making.

Analyst Ratings
SVB Leerink Market Perform Mar 23, 21
SVB Leerink Outperform Feb 5, 21
Raymond James Market Perform Jan 8, 21
Truist Securities Hold Dec 16, 20
Citigroup Neutral Dec 15, 20
Credit Suisse Neutral Dec 14, 20
BMO Capital Market Perform Dec 14, 20
Baird Neutral Dec 14, 20
SVB Leerink Outperform Dec 14, 20